AU Patent

AU2024268271A1 — Methods of treating squamous cell carcinoma with a farnesyltransferase inhibitor and a pi3k inhibitor

Assigned to Kura Oncology Inc · Expires 2025-11-06 · 1y expired

What this patent protects

Provided herein are methods of using Compound (I), or a pharmaceutically acceptable form thereof, optionally in combination with a P13K inhibitor, such as alpelisib, for treating squamous cell carcinoma.

USPTO Abstract

Provided herein are methods of using Compound (I), or a pharmaceutically acceptable form thereof, optionally in combination with a P13K inhibitor, such as alpelisib, for treating squamous cell carcinoma.

Drugs covered by this patent

Patent Metadata

Patent number
AU2024268271A1
Jurisdiction
AU
Classification
—
Expires
2025-11-06
Drug substance claim
No
Drug product claim
No
Assignee
Kura Oncology Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.